Best Medical Weight Loss Platforms 2026

Our recommendation

Ro is our top-scoring pick in Medical Weight Loss Platforms, at 9.8/10 — it highlights “GLP-1 access with clinician care”.

Found sits just 0.2 behind at 9.6, close enough that the deciding factor is usually which specification matters more to you — it highlights “Personalized medication plans”.

Both scores are our editors’ assessment of published specifications, pricing and terms against the criteria in our rating methodology — they are not aggregated customer reviews.

What makes a programme "medical"

The phrase distinguishes clinician-supervised treatment from commercial diet plans. A genuine medical programme should include an assessment by a licensed clinician, review of your history and current medications, baseline laboratory work where clinically indicated, a prescription only if appropriate, and scheduled follow-up to monitor response and side effects. If a service offers a prescription without any of that, what you are buying is fulfilment, not care.

Programmes generally combine some mix of prescription medication, nutrition and behavioural support, and monitoring. The evidence is consistent that medication works best alongside dietary and activity change rather than instead of it, and that structured behavioural support improves results.

The medication landscape, in general terms

Most current interest concerns GLP-1 receptor agonists and related incretin therapies — semaglutide and tirzepatide are the widely discussed examples — which act on appetite regulation and gastric emptying. Older options include phentermine, which is a short-term stimulant appetite suppressant, orlistat, which reduces fat absorption, and combination products. Each has a distinct mechanism, side-effect profile and set of contraindications.

Common gastrointestinal side effects with the incretin class include nausea, vomiting, constipation and diarrhoea, usually most pronounced when starting or increasing a dose. More serious risks discussed in prescribing information include pancreatitis, gallbladder disease, and a boxed warning regarding thyroid C-cell tumours observed in rodent studies, with these medicines contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. There are also important interactions and precautions around pregnancy, diabetes medications and planned surgery or anaesthesia.

Which medication is appropriate, at what dose, and whether any is appropriate at all is a clinical decision specific to you. Nothing here is a recommendation to take a particular drug.

Eligibility

Prescribing for weight management generally follows criteria based on body mass index — commonly a threshold around 30, or around 27 when accompanied by a weight-related condition such as type 2 diabetes, hypertension, sleep apnoea or dyslipidaemia. Programmes should decline patients outside their scope rather than stretching the criteria, and should screen for eating disorders, pregnancy, and conditions that make treatment inadvisable.

Compounded versus FDA-approved products

This is the most important consumer-protection issue in the category. Shortages of branded incretin medicines led to widespread sale of compounded versions, which are not FDA-approved products and have not gone through the same review for safety, efficacy, quality or consistency. Regulators have warned about dosing errors, unapproved salt forms of the active ingredient, and products sold by entities operating outside legitimate pharmacy oversight, including sellers marketing material as "research use only".

If a programme offers a compounded product, reasonable questions are: which pharmacy compounds it and is it a licensed and inspected facility, what exactly is the active ingredient and its form, how is the dose measured and by whom, and what happens if you have an adverse reaction. Prices far below the market for branded equivalents are a signal to ask more questions, not fewer.

What it costs, and what insurance actually does

Coverage for weight-management medication is inconsistent. Many plans exclude it outright, some cover it only with documented prior authorisation, evidence of prior attempts, or specific diagnoses, and some cover it for diabetes but not for weight alone. Employer plans have been narrowing coverage as costs rise. Check your plan's formulary and prior-authorisation requirements before assuming any coverage exists.

Cash-pay costs for branded incretin medicines are substantial — commonly several hundred dollars a month, sometimes more — and are usually separate from the programme's own consultation or membership fee. Manufacturer savings programmes exist but often require commercial insurance and exclude government plans. When comparing programmes, ask for the total monthly cost including medication, consultations, laboratory work and shipping, and what happens to the price after any introductory period.

The question people ask last and should ask first

What happens when you stop? Clinical trial evidence indicates that much of the weight lost with incretin medication is regained after discontinuation, which reframes these as treatments for a chronic condition rather than a course to complete. That has real financial implications: consider whether the cost is sustainable indefinitely, and what the programme's plan is for maintenance, tapering or transition. A programme that will not discuss this candidly is not planning for your actual situation.

Warning signs

• A prescription issued with no clinician interaction, no history taken and no laboratory work.
• No named, licensed, verifiable prescriber, or no way to reach one about side effects.
• Promised amounts or rates of weight loss, or before-and-after claims presented as typical results.
• Pressure to buy long prepaid packages, or subscriptions that are difficult to cancel.
• Vagueness about the source and composition of a compounded medication.

This is general information, not medical advice, and it is not a recommendation for or against any medication. Prescribing information, regulatory guidance, availability and insurance coverage change; discuss your own health, medications and options with a licensed clinician, and consult current FDA information about any product you are considering.